Meet & Greet the ONCOLOGY Board Members and Editorial Team at ASH 2018

Data shown at ASH 2024 demonstrated higher OS rates with anti-CD20 antibodies in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

For patients with HMA–naive chronic myelomonocytic leukemia, an IO-202 combo demonstrated durable responses, a phase 1b study found.

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Active monitoring had similar rates of invasive cancer in the ipsilateral breast as guideline concordant care for the low-risk DCIS population.

Real-world data from the P-VERIFY study didn’t find any notable OS improvements between multiple CDK4/6 inhibitor combos in metastatic breast cancer.